CompletedNCT07184125

Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Study

It focuses on anxiety and currently lists study information in Pakistan.

AnxietyObservationalUp to 60 Years

The study in practice

Understand this study

Listed age limits: up to 60 years.

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study start dateStarted: August 30, 2024

Recruitment status: Completed
Enrollment listed in the registry: 124
Sponsor: Shaukat Khanum Memorial Cancer Hospital & Research Centre
Sponsor type: Hospital / academic medical center
Study type: Observational
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Pakistan
Age range: Up to 60 Years
Official registry ID: NCT07184125
Official title: Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Study

Completed

Lahore

FAQ

Who is behind this study?

The study sponsor is Shaukat Khanum Memorial Cancer Hospital & Research Centre, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including To measure anxiolysis, satisfaction level of patient after receiving Midazolam.

Who was this study for?

Listed age limits: up to 60 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.